Presently, Over 240 Adc Therapy Candidates Are Being Evaluated In Clinical / Preclinical Stages For

By Author: Roots Analysis
Total Articles: 43
Comment this article

With six marketed drugs, ADCs are presently recognized as a potent class of targeted anticancer therapies, with the potential to be used to treat a variety of other disease indications. The success of such products can be attributed to their ability to effectively identify and eliminate disease associated cells / pathogens, with substantially lower risk of treatment related side effects.

To order this 600+ page report, which features 190+ figures and 280+ tables, please visit this link

The USD 15 billion (by 2030) financial opportunity within this market has been analyzed across the following segments:
 Type of Payload
 MMAE
 DM4
 Camptothecin
 DM1
 MMAF
 Others

 Type of Linker
 VC
 Sulfo-SPDB
 SMCC
 VA
 Hydrazone
 Others

 Target Indication
 Breast cancer
 Lymphoma
 Leukemia
 Urothelial cancer
 Lung cancer
 Ovarian cancer
 Others

 Target Antigen
 CD30
 HER2
 CD22
...
...  CD33
 Others

 Technology Providers
 Seattle Genetics
 ImmunoGen
 StemCentRx
 Immunomedics
 Others

 Key Geographical Regions
 North America
 Europe
 Asia Pacific

The Antibody Drug Conjugates Market (5th Edition), 2019-2030 report features the following companies, which we identified to be key players in this domain:
 Bristol Myers Squibb
 GlaxoSmithKline
 Incyte
 Novartis
 Trillium Therapeutics

Table of Contents

1. Preface

2. Executive Summary

3. Introduction

4. Market Overview

5. Company and Drug Profiles

6. Key Therapeutic Areas

7. Key Opinion Leaders

8. Target Competitiveness Analysis

9. Partnerships and Collaborations

10. Funding and Investment Analysis

11. Patent Analysis

12. Academic Grants

13. Key Commercialization Strategies

14. Promotional Analysis

15. Combination Therapies

16. Novel Conjugation Technology Platforms

17. Assessment of Non-Clinical Data, First in Human Dosing

18. Cost Price Analysis

19. Case Study: Contract Manufacturing of ADC

20. Case Study: Companion Diagnostics for ADC Therapeutic

21. Market Forecast and Opportunity Analysis

22. Swot Analysis

23. Conclusion

24. Executive Insights

25. Appendix 1: Tabulated Data

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/antibody-drug-conjugates-market-5th-edition-2019-2030/270.html

Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com